The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug ...